Pharmacy Drugs
Recent Posts
- EPIX Pharmaceuticals Announces FDA Approval Of A Physician-Sponsored IND For Fourth 6-month Open Label Extension Of PRX-03140 For Alzheimer’s Disease
- Miriam Hospital Researcher Receives More Than $12 Million To Study Weight Control
- Novel HIV Drug To Be Studied In Cell Cultures And Patients
- ISCTM Meeting Discusses Clinical And Regulatory Aspects Of Using Adaptive Designs In Clinical Trials For Central Nervous System Drug Approvals
- Evaluation Of The Cost Effectiveness Of Implantable Blood Pressure Device
Random Posts
- ZIOPHARM Presents Positive Palifosfamide Sarcoma Randomized Phase II Interim Data At Annual Meeting Of The Connective Tissue Oncology Society
- Plexxikon Announces PLX4032 Phase 1 Data Showing Objective Responses In Metastatic Melanoma Patients
- Shire Submits European Marketing Authorization Application (MAA) For Velaglucerase Alfa For The Treatment Of Type 1 Gaucher Disease
- FDA Approves Heart Drug After New Trials
- Cegedim Dendrite Launches Innovative COUNTERxFEIT DETECT Program
- Cerus Corporation Receives FDA Blood Products Advisory Committee Guidance For Proposed INTERCEPT Blood System Phase III Trial Design
- PAION AG: Phase Ib And IIa Studies Of The Anesthetic/Sedative CNS 7056 On Track
- MorphoSys Receives Regulatory Approval To Start Phase 1b/2a Clinical Trial For MOR103 Program
- Eurand Successfully Completes Registration Procedure For Paracetamol ODT 250 And 500 Mg In The European Union
- Novel Scleral Lens Proves Clinically Beneficial In Patients Who Have Failed Conventional Therapies
Watson Pharmaceuticals Receives A Complete Response Letter For Its 24-Week Formulation Of TRELSTAR(R) (triptorelin Pamoate) NDA From US FDA
Posted by: admin in Pharmacy Drugs on August 23rd, 2009
Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced that it received a Complete Response Letter from the U.S.